News and Publications
No upcoming events.
Please check back soon for updated 2021/2022 schedule.
PRESS RELEASES
See the latest news and information on our clinic.
High Point Clinical Trials Center Announces the Presentation of Three Posters at the American College of Clinical Pharmacology Meeting
High Point Clinical Trial Center (HPCTC), North Carolina’s premier clinical research facility conducting complex clinical pharmacology testing in Healthy Participants and a wide range of Patient populations is proud to announce the approval of three posters for the 2018 annual American College of Clinical Pharmacology meeting.
Read MoreHigh Point Clinical Trials Center Offers Free Screenings as Part of International NASH Day
High Point Clinical Trials Center (HPCTC), North Carolina’s premier clinical research facility conducting clinical pharmacology testing of potential metabolic disease therapies, is offering free NASH screenings (nonalcoholic steatohepatitis) to those in the public at elevated risk for this largely underdiagnosed disease…
Read MoreHigh Point Clinical Trials Center Appoints Melanie Fein, M.D., CPI, DABFM as Medical Director
High Point Clinical Trials Center (HPCTC), the largest clinical pharmacology facility in North Carolina providing early stage clinical research services, proudly welcomes the return of Dr. Melanie Fein as the organization’s Medical Director…
Read MoreHIGH POINT CLINICAL TRIALS CENTER AND AMYNDAS PHARMACEUTICALS ANNOUNCE THE COMPLETION OF THE COMPLEMENT C3 INHIBITOR AMY-101 FIRST IN HUMAN STUDY
High Point Clinical Trial Center (HPCTC) and Amyndas Pharmaceuticals jointly announce the completion of the AMY-101 First in Human (FIH) study, which assessed, safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD)…
Read MoreHigh Point Clinical Trials Center Announces the Launch of Renal Impairment Clinical Study Offering
High Point Clinical Trials Center (HPCTC) has successfully launched its latest clinical study offering in Renal Impairment. The increasing demand from the pharmaceutical industry to understand the pharmacokinetic impact of novel drugs in renally compromised Patients has prompted…
Read MoreHigh Point Clinical Trials Center Appoints Clayton Dehn, M.S. as Vice President of Clinical Pharmacology Services
HPCTC is pleased to announce that Clayton Dehn, M.S., has joined the company as Vice President of Clinical Pharmacology Services, reporting to Dr. Lorraine M. Rusch, President. Clayton will lead Clinical Pharmacology Services and act as…
Read MoreHigh Point Clinical Trials Center Unveils Community Screening Outreach RV
The conversion of a Recreational Vehicle (RV) to a mobile screening and medical information unit will support High Point Clinical Trials Center’s (HPCTC) volunteering initiatives in…
Read MoreHigh Point Clinical Trials Center Announces Initiative Providing Free Medical Screenings to Community
iCardiac Technologies will assist High Point Clinical Trials Center’s volunteer outreach efforts through donation of electrocardiogram and spirometry equipment.
High Point Clinical Trials Center (HPCTC) announced today a joint initiative with iCardiac Technologies, Inc. to support the patient outreach efforts undertaken by…
Read MoreHigh Point Clinical Trials Center Partners with Verified Clinical Trials to Ensure Participant Safety and Data Quality
High Point Clinical Trials Center announced that it has partnered with Verified Clinical Trials (VCT), the global clinical trials database registry, to ensure
…
Read MorePUBLICATIONS
Read the latest publications by our staff and about our clinic.
Hyperuricemia May Be a Suitable Cost-containing Screening Gateway for Determining NASH
C.A. Dehn, N. McDonald, M. Fein, M. Pearson, L. Galitz, L. Rusch
Clinical Pharmacology in Drug Development
2018, The American College of Clinical Pharmacology
Comparing FibroScan Results Between African- American and Caucasian Populations
M. Pearson, L. Galitz, M. Fein, L. Rusch, C.A. Dehn, N. McDonald
Clinical Pharmacology in Drug Development
2018, The American College of Clinical Pharmacology
Insulin Regulates Circulating Omentin, Fatty Acid Binding Protein-4 and Chemerin, but not Irisin in Man
Nandita K. Shankar, Clayton A. Dehn, Robert V. Considine and Helmut O. Steinberg
High Point CTC: Largest Commercial Clinical Research Facility in NC
Published in The High Point Enterprise
Pathway for NAFLD and NASH drug development in early phase clinical trials
Sabina Paglialunga, Clayton A. Dehn
Clinical assessment of hepatic de novo lipogenesis in NAFLD
Sabina Paglialunga, Clayton A. Dehn
The Time and Quality Advantages of Electronic VAS Scale vs. Paper VAS Scale Utilization in Studies
Jonathan Austin M.D., Lorraine Rusch Ph.D., Mark Pearson M.D., Margarita Nunez M.D.
Opioids for the Treatment of Pain: The Risk of Treating a Multivariate Symptom
Frederick A. Curro, DMD, PhD, FCP
The Journal of Clinical Pharmacology 2017, 57(6) 687–689
2017, The American College of Clinical Pharmacology
DOI: 10.1002/jcph.918